{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Metastatic+Castrate+Resistant+Prostate+Cancer&page=2",
    "query": {
      "condition": "Progressive Metastatic Castrate Resistant Prostate Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Metastatic+Castrate+Resistant+Prostate+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T09:21:29.034Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03490838",
      "title": "177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "177Lu-PSMA-R2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2018-05-24",
      "completion_date": "2022-06-02",
      "has_results": false,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03490838"
    },
    {
      "nct_id": "NCT04104893",
      "title": "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2020-02-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04104893"
    },
    {
      "nct_id": "NCT02106507",
      "title": "ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2014-04",
      "completion_date": "2021-06-28",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106507"
    },
    {
      "nct_id": "NCT01828476",
      "title": "Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "ABT-263",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2013-06",
      "completion_date": "2016-03-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-04",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828476"
    },
    {
      "nct_id": "NCT03939689",
      "title": "I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Prostatic Neoplasm",
        "Cancer of the Prostate",
        "Progressive mCRPC"
      ],
      "interventions": [
        {
          "name": "I-131-1095",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Progenics Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2019-05-30",
      "completion_date": "2024-09-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03939689"
    },
    {
      "nct_id": "NCT01091103",
      "title": "Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Progressive Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2010-02-18",
      "completion_date": "2013-08-31",
      "has_results": true,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091103"
    },
    {
      "nct_id": "NCT06894511",
      "title": "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "AAA617",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2025-09-11",
      "completion_date": "2026-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 5,
      "location_summary": "Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894511"
    },
    {
      "nct_id": "NCT04886986",
      "title": "Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "225Ac-J591",
          "type": "DRUG"
        },
        {
          "name": "177Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "177Lu-PSMA-I&T",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 42,
      "start_date": "2021-06-30",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 2,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886986"
    },
    {
      "nct_id": "NCT04495179",
      "title": "A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progressive Metastatic Castrate-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD4635",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "150 Years",
        "sex": "MALE",
        "summary": "18 Years to 150 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-04",
      "completion_date": "2022-08-08",
      "has_results": true,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495179"
    },
    {
      "nct_id": "NCT02881242",
      "title": "Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2018-01-30",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-01",
      "last_synced_at": "2026-07-23T09:21:29.034Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02881242"
    }
  ]
}